ADTX Aditxt Inc.

1.6
+0.06  (+4%)
Previous Close 1.54
Open 1.55
52 Week Low 1.54
52 Week High 6.73
Market Cap $32,443,728
Shares 20,277,330
Float 18,210,104
Enterprise Value $33,859,369
Volume 1,194,345
Av. Daily Volume 4,399,506
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ADi
Psoriasis
Phase 1/2
Phase 1/2
Phase 1/2 trial planned.

Latest News

  1. Initial AditxtScore testing found one-third of fully vaccinated assisted living community residents needed booster vaccinations to strengthen individual antibody response

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with SphereDX, an advanced clinical diagnostic lab focusing on next-generation genomic and metabolomic clinical testing, to offer its AditxtScore for COVID-19. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual's immune…

    Initial AditxtScore testing found one-third of fully vaccinated assisted living community residents needed booster vaccinations to strengthen individual antibody response

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with SphereDX, an advanced clinical diagnostic lab focusing on next-generation genomic and metabolomic clinical testing, to offer its AditxtScore for COVID-19. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual's immune response to COVID-19.

    Under the agreement, SphereDX will make the AditxtScore for COVID-19 available throughout its laboratory locations serving Kentucky, Ohio and Indiana. The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.

    "There is so much uncertainty out there right now with Kentucky hospitals experiencing critical staffing shortages, kids starting to go back to school, and businesses re-opening during a dramatic surge in COVID-19 cases. By making the AditxtScore for COVID-19 available to our providers and patients, we are able to offer the most detailed, accurate view of individual immune response, giving people the facts they need to make informed decisions about booster vaccinations, return-to-work protocols, mask use and other preventive measures," said Bobby Sturgeon, SphereDX CEO. "The value of this high-fidelity type of antibody testing became immediately clear when we conducted a pilot program in a local assisted living facility, which showed us that roughly one-third of fully vaccinated residents had suboptimal immune responses and required booster shots."

    SphereDX conducted a pilot program deploying the AditxtScore for COVID-19 in a group of area assisted living facilities. Testing a total of 99 fully vaccinated residents ages 63 to 99, the results showed that 33.3% of the residents tested had a suboptimal immune response. Of that group, 8.1% showed no discernable immune response to COVID-19. The CDC has recommended that people with moderately to severely compromised immune systems receive an additional dose of the mRNA COVID-19 vaccine.

    "If we really want to get ‘back to normal' with confidence, we are going to need personalized immune testing that delivers detailed information on the strength and durability of each individual's immune response," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. "We are thrilled to be working with SphereDX to bring that level of certainty and confidence to the people of Kentucky, Ohio and Indiana."

    AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with COVID-19. This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual's immune response in a single test cycle. It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.

    The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual's immune response to COVID-19. This information can be used to guide further intervention for those who have not developed a strong immune response and to reassure those who have developed a strong response that no further action is required.

    This information is particularly important for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body's natural immune response capacity.

    AditxtScore for COVID-19 is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.

    About Aditxt:

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  2. Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has closed on a registered direct offering for $11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent (LOI). Additionally, the Company entered into an agreement with the holder of its outstanding convertible note, whereby the parties agreed to waive certain rights with respect to the convertible note and modify certain provisions of the warrants held by the holder, and pursuant to which the Company can satisfy the note through a combination of the issuance of shares and a cash payment by October 15, 2021, giving it the opportunity…

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has closed on a registered direct offering for $11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent (LOI). Additionally, the Company entered into an agreement with the holder of its outstanding convertible note, whereby the parties agreed to waive certain rights with respect to the convertible note and modify certain provisions of the warrants held by the holder, and pursuant to which the Company can satisfy the note through a combination of the issuance of shares and a cash payment by October 15, 2021, giving it the opportunity to clear the path for the Company's planned acquisition.

    Aditxt is advancing its negotiations and due diligence under an exclusive LOI to reach a definitive agreement to acquire a biopharmaceutical company that is commercializing a COVID-19 antiviral oral therapy by September 30, 2021.

    The acquisition transaction is subject to numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements, and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The parties have agreed to an exclusivity period until September 30, 2021, with a view to settling the definitive agreement. However, there can be no assurance that a definitive agreement will be entered into or that the proposed acquisition will be completed as proposed or at all.

    The proposed transaction contemplates Aditxt issuing such number of shares of common stock that yields 50% of the number of Aditxt's outstanding shares post-closing of the transaction.

    "We are working diligently to reach a definitive agreement with this acquisition candidate which we believe is a strong synergistic fit with Aditxt's immune health technology and particularly our COVID-19 monitoring test. The acquisition would potentially grow our immune innovation platforms and further advance our commercialization and revenue generating activities," stated Aditxt Co-Founder and CEO Amro Albanna.

    About Aditxt:

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  3. Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into definitive agreements with certain institutional investors to purchase 4,583,334 shares of its common stock at a purchase price of $2.40 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $11.0 million, before payment of commissions and expenses. In a concurrent private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase one share of common stock. The warrants have an exercise price of $2.53 per share, and are exercisable for…

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into definitive agreements with certain institutional investors to purchase 4,583,334 shares of its common stock at a purchase price of $2.40 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $11.0 million, before payment of commissions and expenses. In a concurrent private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase one share of common stock. The warrants have an exercise price of $2.53 per share, and are exercisable for a five year period commencing six months from the date of issuance.

    The Company plans to use the net proceeds of approximately $10.1 million from this offering to fund a $6.5M loan to a biopharmaceutical company commercializing COVID-19 antiviral oral therapy, and for general corporate and working capital purposes, including the purchase of fixed assets.

    Dawson James Securities, Inc. is acting as the exclusive placement agent for the offerings.

    The offering of the common stock described above (but not the warrants or the shares of common stock underlying the warrants) is being made pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-257645), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on July 13, 2021. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement. A prospectus supplement and accompanying prospectus related to the offering of common stock will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock may be obtained, when available, by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, FL, 33432, cwachowiz@dawsonjames.com or toll free at 866.928.0928.

    The warrants issued in the concurrent private placement and shares of common stock underlying the warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About Aditxt

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements in this press release include, without limitation, the ability of the Company to close the offering. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  4. Target Acquisition Has Operational and Sales Footprint in Europe, Asia, and the Middle East

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it has signed a letter of intent ("the LOI") to acquire a biopharmaceutical company, the "Target Company", commercializing COVID-19 antiviral oral therapy. The Target Company is currently selling its products under emergency and compassionate use, standard of care, and full approval in multiple countries internationally outside of the U.S. and Canada.

    The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and…

    Target Acquisition Has Operational and Sales Footprint in Europe, Asia, and the Middle East

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it has signed a letter of intent ("the LOI") to acquire a biopharmaceutical company, the "Target Company", commercializing COVID-19 antiviral oral therapy. The Target Company is currently selling its products under emergency and compassionate use, standard of care, and full approval in multiple countries internationally outside of the U.S. and Canada.

    The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The parties have agreed to an exclusivity period until September 30, 2021, with a view to settling the definitive agreement. However, there can be no assurance that a definitive agreement will be entered into or that the proposed acquisition will be completed as proposed or at all.

    Key terms of the proposed transaction as stated in the LOI include: the completion of a proposed $6.5M secured loan from Aditxt to the Target Company by August 31, 2021, as well as Aditxt issuing such number of shares of common stock that yields 50% of the number of Aditxt's outstanding shares post-closing of the transaction.

    "We have been eager to grow the global footprint of Aditxt's immune therapeutic and monitoring platforms," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. "We are also excited about this potential transaction, which, if completed, would be a complementary strategic fit with our company."

    About Aditxt:

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  5. AditxtScore™ for COVID-19 now offered in Great Lakes Medical Laboratory locations, allowing Michiganders and their physicians to monitor and evaluate their COVID-19 immune response

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a full-service medical reference laboratory, to offer its AditxtScore™ for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an…

    AditxtScore™ for COVID-19 now offered in Great Lakes Medical Laboratory locations, allowing Michiganders and their physicians to monitor and evaluate their COVID-19 immune response

    Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a full-service medical reference laboratory, to offer its AditxtScore™ for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual's immune response to the SARS-CoV-2 virus.

    Under the agreement, GLML will make the AditxtScore for COVID-19 available throughout its six physical locations and mobile units in Michigan. The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.

    "We were drawn to Aditxt initially because it has the most comprehensive COVID-19 immune testing solution available, allowing us to give people clarity about their individual immune response to COVID-19," said Elizabeth Knisely, Chief Executive Officer of GLML. "What I did not expect was that after receiving an AditxtScore myself I would find that I had low immune response, despite being vaccinated. With so much uncertainty out there right now around a surge in breakthrough cases, we need to take the guesswork out of the equation especially for patients who are vulnerable and immunocompromised."

    AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with COVID-19. This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual's immune response in a single test cycle. It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles. The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual's immune response to COVID-19.

    "While we have seen an increase in the number of COVID-19 vaccines administered in Michigan, just under half of our population is still not vaccinated and vaccine hesitancy remains a significant challenge in our rural and urban areas," said Samar Nasry, MD, internal medicine specialist and Director of the Medical Care1 Urgent Care in Michigan. "A lot of the hesitancy we're seeing is driven by misinformation, potential infection post vaccination, and uncertainty about individual risk. The wide availability of the AditxtScore for COVID-19 will help us address those challenges by giving people the hard facts about their immune status."

    This information is particularly important for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body's natural immune response capacity.

    "We're thrilled to be working with GLML to bring our AditxtScore for COVID-19 to the state of Michigan," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. "Everyone's immune response is unique to that individual, so it's critical to evaluate each individual's immune response in order to effectively address this pandemic. Our AditxtScore for COVID-19 delivers that personalized approach with the accessibility and efficiency needed to scale."

    AditxtScore for COVID-19 is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.

    About Aditxt:

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
View All Aditxt Inc. News